ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Key Takeaway: ImmunityBio has responded to recent correspondence from the FDA regarding its advertising practices. The company has reaffirmed its commitment to compliance with advertising regulations. Further details on the specific nature of the correspondence were not disclosed in the article.